Advertisement

Topics

Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study.

08:00 EDT 24th August 2018 | BioPortfolio

Summary of "Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study."

Safinamide (Xadago) is a newly approved selective MAO-B inhibitor for the treatment of Parkinson's Disease (PD). The X-TRA study investigated the efficacy and tolerability of the substance under clinical practice conditions.

Affiliation

Journal Details

This article was published in the following journal.

Name: Fortschritte der Neurologie-Psychiatrie
ISSN: 1439-3522
Pages:

Links

DeepDyve research library

PubMed Articles [41966 Associated PubMed Articles listed on BioPortfolio]

Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia.

Safinamide (Xadago®) is a novel dual mechanism drug which has been approved in the EU and US as add-on treatment to levodopa in Parkinson's disease (PD) therapy. In addition to its selective and reve...

Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.

Istradefylline is a first-in-class, non-dopaminergic, selective adenosine A receptor antagonist for the treatment of Parkinson's disease (PD) in patients experiencing the wearing-off phenomenon with l...

Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation ...

Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.

Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease-modifying effect could provide guidance as to when in the course of the disease the ...

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.

Human gut microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease. In this study, we characterize gut-associated bacteria ...

Clinical Trials [15156 Associated Clinical Trials listed on BioPortfolio]

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

The objective of this study is to investigate the effect of safinamide on levodopa blood levels, both after single and multiple dosing of safinamide . A further objective of the study is t...

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

The purpose of this research trial is to determine in Parkinson's disease patients if safinamide (experimental drug) can attenuate the dyskinesia induced by levodopa. The word "experimenta...

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) defi...

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

This is a Phase IV, international, multicentre, randomised, double-blind, placebo controlled study in IPD patients, experiencing motor fluctuations and PD related chronic pain while on sta...

Intravenous Levodopa for the Diagnosis of Parkinson's Disease

Patients with Parkinson's disease have low levels of the neurotransmitter dopamine. Dopamine is responsible for motor function and normal physical activity. Patients with Parkinson's dise...

Medical and Biotech [MESH] Definitions

A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.

Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, practicability, etc., of these interventions in individual cases or series.

Proteins associated with sporadic or familial cases of PARKINSON DISEASE.

A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...


Searches Linking to this Article